Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It
clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. The company trades on NASDAQ exchange. The company headquarter is located in Radnor, PA. The company was established in the 2019.
| Ticker | MLYS |
| Long Name | Mineralys Therapeutics, Inc. |
| Short Name | Mineralys Therapeutics |